SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2008 / Cilt: 23 - Sayı: 1

Cisplatin-based concomitant chemoradiotherapy in locally advanced squamous cell carcinoma of head and neck: Toxicity and feasibility analysis

Lokal ileri evre skuamöz hücreli baş ve boyun kanserinde sisplatinle eş zamanlı kemoradyoterapi: Yan etki ve uygulanabilirlik analizi

Perran Fulden YUMUK
Züleyha AKGÜN
Faysal DANE
Meriç ŞENGÖZ
Beste Melek ATASOY
Nazım Serdar TURHAL
Murat SARI
Ufuk ABACIOĞLU
Pages
1–11
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Initial Karnofsky Performance Status (KPS) significantly predicted concurrent chemotherapy completeness (KPS ≥90, 63.8% vs KPS

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVES In this study, we assessed the side effects and the factors related to patients, disease and, treatment that might change the decision for concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer.
📊
Key Findings & Data:METHODS A total of 65 patients (49 primary; 16 postoperative) who received curative radiotherapy (median 70 Gy) with conventional fractionation schedule were enrolled into the study.
💡
Conclusion & Impact:Initial Karnofsky Performance Status (KPS) significantly predicted concurrent chemotherapy completeness (KPS ≥90, 63.8% vs KPS
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVES In this study, we assessed the side effects and the factors related to patients, disease and, treatment that might change the decision for concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer. METHODS A total of 65 patients (49 primary; 16 postoperative) who received curative radiotherapy (median 70 Gy) with conventional fractionation schedule were enrolled into the study. Concomitant cisplatin were administered either 60-80 mg/m2 every 3 weeks (n=57) or 40 mg/m2 weekly (n=8).RESULTS Concurrent chemotherapy was completed in 46.1% patients. Premature chemotherapy termination was done due to grade 3 adverse event (41.6%), patients’ refusal (19.4%) or physician decision (33.3%). Initial Karnofsky Performance Status (KPS) significantly predicted concurrent chemotherapy completeness (KPS ≥90, 63.8% vs KPS

Özet

AMAÇ Bu çalışmada, lokal ileri evre skuamöz hücreli baş ve boyun kanseri tanılı hastalarda eş zamanlı kemoradyoterapi (KRT) sırasında görülen yan etkiler analiz edilmiş, hasta, hastalık ve tedaviye bağlı faktörlerin eş zamanlı tedavinin tamamlanabilirliği üzerine etkisi incelenmiştir. GEREÇ VE YÖNTEM Kliniğimizde 2001-2007 yılları arasında konvansiyonel radyoterapi şemasıyla ortanca 70 Gy (50-73 Gy) tedavi görmüş 49’u primer, 16’sı adjuvan toplam 65 hasta çalışmaya dahil edildi. Hastalara eş zamanlı sisplatin 3 haftada bir 60-80 mg/m2 (n=57) ya da haftalık 40 mg/m2 (n=8) olarak uygulandı.BULGULAR Eş zamanlı kemoterapi hastaların % 4 6,1’inde planlanan şekilde uygulanabildi. Kemoterapi durdurma nedenleri arasında derece 3 ve üzeri yan etki (%41,6) yanında hasta reddi (%19,4) ve hekim kararı (%33,3) vardı. Radyoterapi öncesi Karnofsky Performans Durumu (KPS) ≥90 olan hastalarda eş zamanlı sisplatinin tamamlanma oranı %63,8 iken, bu oran KPS

🔖

Cite This Article

YUMUK, P. F., AKGÜN, Z., DANE, F., ŞENGÖZ, M., ATASOY, B. M., TURHAL, N. S., SARI, M., ABACIOĞLU, U. (2022). Cisplatin-based concomitant chemoradiotherapy in locally advanced squamous cell carcinoma of head and neck: Toxicity and feasibility analysis. Türk Onkoloji Dergisi, Cilt: 23 - Sayı: 1, 1–11. https://ajindex.com/articles/639359

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48(1):7-16
  2. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L; Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer Disease Site Group. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 2001;23(7):579-89
  3. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta analysis. Lancet 2006;368(9538):843-54
  4. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three metaanalyses of updated individual data. MACH-NC Collaborative Group. Meta Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355(9208):949 55
  5. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data metaanalysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64(1):47-56
  6. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16(4):1310-7
  7. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937 44
  8. Glynne-Jones R, Sebag-Montefiore D. Chemoradiation schedules-what radiotherapy? Eur J Cancer 2002;38(2):258-69
  9. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 2000;47(1):1-12
  10. Available from: http://ctep.cancer.gov/forms/CTCv20 _4-30-992.pdf 11) LENT SOMA tables. Radiother Oncol 1995;35(1):17- 60
  11. Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiat Oncol 2007, in press
  12. Marcu L, van Doorn T, Olver I. Cisplatin and radiotherapy in the treatment of l